RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 BEAUTIFUL Trial Fails to Meet Primary Endpoint
JF MD Conference Express
YR 2008
FD SAGE Publications
VO 8
IS 6
SP 12
OP 13
DO 10.1177/155989770800800604
UL http://mdc.sagepub.com/content/8/6/12.abstract
AB Although the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary artery disease and left ventricULar dysfunction [BEAUTIFUL; NCT00143507] trial failed to meet its primary composite endpoint of cardiovascular death, admission to hospital for acute myocardial infarction (MI), and hospitalization for new-onset or worsening heart failure, it significantly reduced important secondary endpoints, such as hospitalization for fatal or non-fatal MI and coronary revascularization.